Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE). The Fast Track designation process aims to facilitate the development and expedite the review of new medicines that treat serious conditions and fill unmet medical needs, with the goal of delivering potentially important therapies to patients sooner.
Read more: https://prn.to/2PBvKt5

Viracor Eurofins announced the recent launch of a new 16S Next Generation Sequencing (NGS) Bacterial Meningitis test for use in patients suspected of having bacterial meningitis. Physicians will receive test results for difficult-to-diagnose immunocompromised patients within 3 business days from specimen receipt. Knowing the specific pathogen involved in central nervous system (CNS) infection is crucial for selection of the appropriate therapeutic to achieve rapid recovery and to minimize the risk of permanent CNS damage. Viracor is expanding its test menu to include this and other NGS testing in support of enhanced pathogen detection and transplant rejection assessment.
Read more: https://prn.to/2QWwXA9

See how big pharma are scaling and measuring patient centricity with Novartis, Janssen and Bayer.
Free copy available here: http://bit.ly/2PkqXMB
#patientcentricity #precisionmedicine #bigpharma #medical #healthcare #pharmaceutical

Biohaven Pharmaceutical Holding Company Ltd. today announced initial positive results from its ongoing long-term, open-label safety study of its oral calcitonin gene-related peptide (CGRP) receptor antagonist, rimegepant, for the acute treatment of migraine. Based upon this interim analysis (database cutoff of November 21, 2018) of Study BHV3000-201 (NCT03266588 or "Study 201") it appears that rimegepant may be safe and well tolerated with long-term dosing in patients with migraine. In this study, patients are allowed to treat migraine attacks of all severities (mild to severe) up to once daily for up to a full year.
Migraine is both a widespread and disabling neurological disorder. The Migraine Research Foundation ranks migraine as the world's third most prevalent illness, affecting approximately 36 million people or 1 out of 4 households in the United States. And the Global Burden of Disease Study 2015 rates migraine as the seventh highest specific cause of disability worldwide. More than 90% of migraine sufferers are unable to work or function normally during an attack.
Read more: https://prn.to/2QspYQ0

Measuring Motion, Delivering Insights: Actigraphy Motion Biosensors wearable devices provide objective nocturnal scratching event measurement to evaluate the impact of a particular therapy or medication pertaining to Atopic Dermatitis.

What ever your specialty don't limit your studies just to a single field grab any opportunity that comes your way as far as it will help you discover something new. The world is very dynamic and diverse. Let's not limit our studies likewise our brains, expand the scope

I am a recent MBA graduate seeking a firsthand opportunity in the Pharmaceutical field. Willing to learn and improve my experience. Looking for an opportunity to grow with a company!

Migali Scientific manufactures a complete line of pharmacy, laboratory, blood bank, vaccine storage and medical-grade refrigerators and freezers for the life sciences community. If you are interested in any the products, or would like to know more about the brand, please drop me a note.

Dear Recruiters:

Good day;

I'm currently seeking for Job Opportunity especially at a multinational Pharmaceutical Organizations. 

I have technical experience of about 17 years+ Having Master degree + Having Total Quality management  Diploma from American University at Cairo.

I'm liable to work at European countries if a challenging job opportunity is available.

You can have a look on my LinkedIn profile through the following link:

https://www.linkedin.com/in/eman-hamdi-ahmed-7431463b

Yours;

Eman Hamdi

002-01007447877

It is very important  in estimating new investments in near future

Registration Department and R & D Registration Department and R & D 

Registration Department and R & D 

Impact on the pharma industry 

some drugs are  not directly absorbed in systemic circulation these drugs cannot be identified by invivo BA &BE  for those compounds we need to do invitro conditions and these drugs helpful in Renal failure patients like Ferric citrate, Sevelamer Carbonate, Sevelamer HCL,Sucroferric oxyhydroxide.Calcium acetate.

Looking forward to completing my studies